Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.64% and ...

A 2018 study in The Lancet found lower grip strength predicted a higher risk of cardiovascular disease, cancer and all-cause ...

The ability to transform cancer cells back into normal cells represents a monumental leap in cancer treatment. With fewer side effects and a reduced risk of recurrence, this technology promises a ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Eli Lilly's Zepbound has become the first drug to be ... glaucoma, diabetes, cancer, and cognitive and behavioural disorders. In trials, Lilly's dual GIP/GLP-1 agonist reduced OSA severity in ...